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Abstract
Purpose—To determine whether lapatinib, a dual epidermal growth factor receptor (EGFR)/HER2
kinase inhibitor, can radiosensitize EGFR+ or HER2+ breast cancer xenografts.
Methods and Materials—Mice bearing xenografts of basal-like/EGFR+ SUM149 and HER2+
SUM225 breast cancer cells were treated with lapatinib and fractionated radiotherapy and tumor
growth inhibition correlated with alterations in ERK1 and AKT activation by immunohistochemistry.
Results—Basal-like/EGFR+ SUM149 breast cancer tumors were completely resistant to treatment
with lapatinib alone but highly growth impaired with lapatinib plus radiotherapy, exhibiting an
enhancement ratio average of 2.75 and a fractional tumor product ratio average of 2.20 during the
study period. In contrast, HER2+ SUM225 breast cancer tumors were highly responsive to treatment
with lapatinib alone and yielded a relatively lower enhancement ratio average of 1.25 during the
study period with lapatinib plus radiotherapy. Durable tumor control in the HER2+ SUM225 model
was more effective with the combination treatment than either lapatinib or radiotherapy alone.
Immunohistochemical analyses demonstrated that radiosensitization by lapatinib correlated with
ERK1/2 inhibition in the EGFR+ SUM149 model and with AKT inhibition in the HER2+ SUM225
model.
Conclusion—Our data suggest that lapatinib combined with fractionated radiotherapy may be
useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to
ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.
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Breast cancer is the most commonly diagnosed cancer among women in the United States. It
arises from different epithelial cell populations, resulting in tumors of basal or luminal origin,
with the basal subtype conferring a worse prognosis (1,2). Several groups have reported the
use of traditional chemotherapy combined with radiotherapy (RT) in attempts to improve local
control (3,4), an approach that has proved to be beneficial in other cancers. However, because
of the significant toxicities seen in these trials, a great deal of interest exists in using targeted
biologic therapies combined with RT to improve local control rates while maintaining
acceptable toxicity (5).
Currently, several targeted biologic therapies are of promising clinical interest against members
of the epidermal growth factor receptor (EGFR/ErbB) family of proteins, including ErbB1/
EGFR/HER1, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4. All four receptors have
been reported to play a role in tumorigenesis and are known to regulate epithelial cell
proliferation, survival, and differentiation (6). The best studied among these family members
remains EGFR and HER2, which are aberrantly expressed in a variety of human malignancies,
including breast cancer. EGFR and HER2 play an important role in radioresistance, with EGFR
positivity associated with a poor prognosis and an unfavorable response to therapy (7,8).
Although it is well established that EGFR and HER2 signal to several downstream effector
pathways, including MEK>ERK and PI3K>AKT, the key pathways that confer EGFR/HER2-
mediated radioresistance are poorly understood (9,10). Clarification of the pathways that
mediate radiosensitization with inhibitors of EGFR/HER2 could potentially advance treatment
options. For instance, with the development of EGFR inhibitor resistance, including the
uncoupling of EGFR to downstream signaling pathways (18), direct inhibition of these
pathways could provide alternative therapeutic targets. Additionally, identifying the relevant
downstream effectors of EGFR/HER2 therapies as radiosensitizers could provide biomarkers
to better predict the tumor response and improve patient selection.
Preclinical studies using a variety of EGFR inhibitors in different model systems have
demonstrated their substantial promise as radiosensitizers (11). Cetuximab (Erbitux, Im-Clone
Systems, New York, NY), a monoclonal antibody targeting EGFR, was the first biologic agent
to show local control and survival advantage when used in combination with RT for patients
with head-and-neck cancer (12). CI-1033 is a small molecule inhibitor that blocks all four
EGFR family members that recently failed in a Phase II trial of metastatic breast cancer patients
because of unacceptable toxicities (13). However, in preclinical studies with CI-1033, breast
cancer cells were effectively radiosensitized with combination therapy (14), providing support
for continued efforts to identify clinically efficacious EGFR inhibitors to radiosensitize breast
cancer tumors. Lapatinib (Tykerb, GlaxoSmithKline, Middlesex, United Kingdom), a small
molecule tyrosine kinase inhibitor with near-equipotent inhibition of both EGFR and HER2,
has been approved for use by the Food and Drug Administration in patients with advanced or
metastatic HER2-overexpressing breast cancer (15). Moreover, a subset of breast cancer
patients exhibiting progression after previous therapy with trastuzumab (Herceptin, Genentech,
Hoboken, NJ), a HER2 monoclonal antibody, have shown benefit with subsequent treatment
with lapatinib (16,17). Whether lapatinib can radiosensitize breast cancers that overexpress
EGFR or HER2 is currently unknown. The purpose of the present study was to determine
whether lapatinib could radiosensitize EGFR- or HER2-overexpressing breast cancer cells in
mouse xenograft models and whether radiosensitization correlates with inhibition of
downstream signaling to MEK>ERK and/or PI3K>AKT.
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Cell lines and reagents
Lapatinib was synthesized and generously provided by GlaxoSmithKline and formulated in
sulfo-butyl-ether-β-cyclodextrin as a 10% aqueous solution. The human breast cancer cell lines
SUM149 and SUM225 were cultured as previously described (18).
Xenograft treatment and tumor harvesting
Animal experiments were performed in accordance with the University of North Carolina
Institutional Animal Care and Use Committee guidelines. Cells (5–10 × 106) were suspended
in 200 μL of a 1:1 ratio of phosphate-buffered saline/Matrigel (BD Biosciences, Franklin Lakes,
NJ) before injection into the flanks of 4–5-week-old female C.B-17 Fox Chase severe combined
immunodeficient mice (Charles River Laboratories, Wilmington, MA). For optimization of
dosing studies, tumors were grown to a diameter of 10 mm and then treated with lapatinib (0,
30, or 100 mg/kg twice daily at 6-h intervals) for a total of five treatments within 2.5 days, as
previously described (19). The mice were sacrificed by carbon dioxide inhalation, and the
tumors harvested 4 h after the last dose of lapatinib and flash-frozen until processing for
immunoprecipitation.
For tumor radiosensitization and immunohistochemical studies, tumors were grown to a
volume of 100 mm3, randomized (n = 8 mice/group), and treated with vehicle, lapatinib, RT,
or both lapatinib and RT. Lapatinib (100 mg/kg twice daily at 6-h intervals) or vehicle (10%
sulfo-butyl-ether-β-cyclodextrin) was administered by oral gavage for 10 days starting at Day
–10. RT was administered at 2 Gy/fraction to anesthetized mice for 3 consecutive days starting
at Day –4 and delivered by a linear accelerator (Primus, Siemens, New York, NY) using 6-
MeV electrons and a custom lead cutout.
Tumors were measured at regular 3-day intervals, and tumor volumes calculated by width ×
length/2. The fold-change in tumor volume was normalized to baseline (Day –10) size and
plotted over the indicated points to generate tumor growth graphs using GraphPad Prism,
version 5.0. Statistical significance was determined using two-way analysis of variance.
Enhancement ratios were determined by dividing the average tumor volumes of tumors
receiving RT alone by those receiving RT plus lapatinib. Tumor growth rates were derived by
determining the slopes of the growth curves for each treatment group.
To assess the antagonistic, additive, and synergistic effects, we used the fractional tumor
product method using values averaged for the study duration starting at Day 0 (20,21), where
a value >1 suggested that the combined treatments were effectively synergistic, <1 antagonistic,
and equal to 1 additive.
Immunohistochemistry
For immunohistochemical analyses, tumors were harvested within 72 h of the last treatment
at Day –1, fixed in 10% buffered formaldehyde for 24 h, embedded in paraffin, and processed
using antigen retrieval buffer (BioGenex, San Ramon, CA). The antibodies used included anti-
phospho-ERK1/2, anti-total ERK1/2, anti-phospho AKT, and anti-total AKT (all from Cell
Signaling Technologies, Beverely, MA), which were incubated overnight at 4°C, along with
appropriate secondary antibodies, and visualized by VECTASTAIN Elite biotin-avidin
complex reaction (Vector Laboratories, Burlingame, CA) with nickel-enhanced
diaminobenzidine (Pierce Invitrogen, Carlsbad, CA.) used as the chromogen and hematoxylin
used as counterstain. All samples were stained in triplicate, and the intensity and percentage
of stained cells scored by a pathologist blinded to the treatment groups and multiplied together
to derive a total immunohistochemical score for phosphorylated ERK1/2 and phosphorylated
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AKT. Statistical analyses were performed using one-way analysis of variance (GraphPad
Prism).
Protein extraction, immunoprecipitation, and Western blotting
To determine EGFR phosphorylation levels in tumor tissue, flash-frozen tissue was pulverized
with mortar and pestle, and lysates prepared and processed with anti-EGFR (polyclonal rabbit
22 antisera), as previously described (18). Western blotting was performed using anti-phospho-
tyrosine antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or anti-EGFR antisera
(polyclonal rabbit 22).
Results
We have previously shown that EGFR and HER2 activation are blocked by lapatinib in EGFR-
overexpressing (EGFR+) basal-like SUM149 and HER2-overexpressing (HER2+) SUM225
breast tumor cells in vitro (18). In the present study, we sought to determine whether lapatinib
could radiosensitize these cells in vivo and whether the response to therapy would correlate
with the inhibition of downstream signaling.
RT plus lapatinib synergistically inhibited tumor growth in basal-like/EGFR+ SUM149
xenografts in vivo
To determine the dose of lapatinib needed to inhibit EGFR in vivo, we evaluated the levels of
phosphorylated EGFR in SUM149 xenografts treated with lapatinib using a dosing scheme
commonly used for HER2+ breast cancer xenograft mouse models (19,22). Partial inhibition
of EGFR phosphorylation was evident after treatment with 30 mg/kg of lapatinib, and full
inhibition occurred with 100 mg/kg (Fig. 1A). This showed that the dosing regimen needed to
inhibit activation of EGFR is similar to that needed to inhibit HER2 in vivo. Thus, we chose
to use the 100 mg/kg dosing regimen for all subsequent breast cancer xenograft
radiosensitization studies.
Next, to investigate whether lapatinib could radiosensitize basal-like EGFR+ SUM149 cells,
the xenografts were allowed to develop palpable tumors and then treated with vehicle, lapatinib,
radiotherapy, or lapatinib plus radiotherapy. No significant difference in tumor growth was
seen between the vehicle and lapatinib-treated xenografts during the study duration (27 days).
In contrast, treatment with RT alone or lapatinib plus RT resulted in tumor growth delay (Fig.
1B). The average fold- increase in tumor volume at study termination (Day 27) was
significantly reduced in the mice treated with lapatinib plus RT (1.53; p <.001) compared with
that in the control mice (20.8) or those treated with lapatinib (22.5) or RT (12.1) alone.
Comparing the average rate of tumor growth per day (Fig. 1C) also showed a significant
reduction with lapatinib plus RT vs. RT alone. The enhancement ratio of the tumors treated
with lapatinib plus RT averaged 2.75 during the study duration (Supplementary Fig. e1) and
was greatest immediately after completion of the study treatments at Day 0 (3.24) and Day 19
(3.20), demonstrating immediate and durable tumor control. To determine whether the
enhanced interaction with lapatinib plus RT was additive or synergistic, the fractional product
method was used and gave an expected/observed fractional tumor volume ratio average of 2.20
during the study duration (Fig. 1D), consistent with a synergistic interaction.
HER2+ SUM225 xenografts are lapatinib sensitive and exhibited enhanced growth delay
when combined with RT
In the HER2+ SUM225 xenografts, the average fold- increase in tumor volume early in the
study at Day 21 was significantly reduced in the mice treated with lapatinib alone (4.44; p <.
01) compared with that in the control mice (12.68). At Day 21, the combination of lapatinib
plus RT did not provide a statistically significant difference in the fold- increase in tumor
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volume compared with RT alone (3.19 vs. 4.89, p = NS), indicating that lapatinib did not
provide radiosensitization at early points in the SUM225 xenografts (Fig. 2A). This was
supported by analyses during the initial 21-day growth period in which the interaction of
lapatinib plus RT was less than additive using the fractional tumor product method (data not
shown). However, although tumors from the control mice and lapatinib-only treatment arms
could not be assessed beyond Days 45 and 81, respectively, tumor regrowth in the RT only
and lapatinib plus RT groups increasingly diverged during the remaining study duration (138
days), with statistically significant differences in the fold- increase in tumor volume (13.99 vs.
3.66, p <.01) starting at Day 97. Comparisons of the average rate of tumor growth daily (Fig.
2B) was also significantly reduced with lapatinib plus RT vs. RT alone. The enhancement ratios
in the mice treated with lapatinib plus RT averaged 1.25 during the study duration (Days 0–
138; Supplementary Fig. e1) and was greatest immediately after completion of the study
treatments (Days 0–10; enhancement ratio, 2.3) and toward study termination at 3 months
(Days 97–138; enhancement ratio, 1.43).
Lapatinib-mediated radiosensitization correlates with inhibition of ERK1/2 in basal-like/
EGFR+ SUM149 and AKT in HER2+ SUM225 xenograft models
We next sought to determine whether lapatinib-mediated radiosensitization correlated with
inhibition of downstream signaling through the MEK>ERK and PI3K>AKT pathways. For
these analyses, tumors were obtained on completion of the study treatments from the
companion mice in each treatment group and analyzed using immunohistochemistry.
Treatment with lapatinib plus RT in the basal-like/EGFR+ SUM149 xenograft tumors showed
a reproducible and significant decrease in cells staining positive for phosphorylated ERK1/2
with a reduced phosphorylated ERK1/2 score (3.7 ± 0.6) compared with RT alone (9.3 ± 1.0;
Fig. 3). No statistically significant difference was found in phosphorylated ERK1/2 levels
between RT alone (9.3 ± 1.0) or lapatinib alone (8.7 ± 0.8) and the control (8.8 ± 0.8). In
addition, no change in phosphorylated AKT levels was seen in any treatment group (data not
shown).
In contrast, the HER2+ SUM225 xenografts showed no change in phosphorylated ERK1/2
levels in any of the treatment arms (data not shown). However, a statistically significant
decrease in phosphorylated AKT was observed in the lapatinib-alone and RT-alone treatment
groups (6.0 ± 0.0 and 6.7 ± 0.7, respectively) compared with the control group (10.0 ± 1.15),
with the largest decrease in phosphorylated AKT observed in the combined lapatinib plus RT
group (1.8 ± 0.4). These data suggest that the mechanism of lapatinib-mediated
radiosensitization differs between breast cancer subtypes, such that basal-like/EGFR+ cells are
sensitized through inhibition of ERK1/2, while in HER2+ cells, sensitization occurs through
inhibition of AKT.
Discussion
We have demonstrated that in mouse xenograft models, the dual EGFR/HER2 inhibitor,
lapatinib, can radiosensitize both HER2+ and basal-like/EGFR+ breast cancer cell lines.
Specifically, we have shown that tumors from SUM149 basal-like/EGFR+ cells were
insensitive to lapatinib monotherapy treatment but were radiosensitized when lapatinib was
combined with RT. In contrast, tumors from SUM225 HER2+ cells were highly sensitive to
lapatinib monotherapy alone and, like the basal-like/EGFR+ cells, showed an enhanced
therapeutic response when lapatinib was combined with RT. In addition, we found that
inhibition of phosphorylated ERK1/2 correlated with radiosensitization in the basal-like/EGFR
+ tumors and inhibition of phosphorylated AKT correlated with the response in HER2+ tumors.
We hypothesized that a subset of breast cancer patients could benefit from a therapeutic
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regimen in which RT is combined with lapatinib for both basal-like/EGFR+ and HER2+ breast
cancers and that the downstream biomarkers of response will differ by subtype.
Inhibitors against the EGFR family of proteins have shown promise as radiosensitizers in
preclinical studies for a variety of cancer types and in clinical studies of head-and-neck cancer
(11,12). Although lapatinib has been approved by the Food and Drug Administration for the
treatment of HER2+ metastatic breast cancer, the EGFR pathway has recently become a
potential target for the basal-like subtype, in which ≥50% of basal-like tumors have been shown
to overexpress EGFR as assessed by immunohistochemistry (23,24). Basal-like breast cancers
represent 16% of all breast cancers, and patients with this subtype of breast cancer face a worse
prognosis and are not candidates for therapies commonly used for other breast cancer subtypes,
such as anti-estrogen receptor or anti-HER2 therapies, because they are typically estrogen
receptor, HER2, and progesterone receptor negative (25). Instead, these patients are treated
with conventional chemotherapy regimens, which have shown limited efficacy. Consistent
with our previous in vitro studies, which showed lapatinib-mediated inhibition of proliferation
in SUM149 cells (18), other groups have also shown that other EGFR inhibitors, including
Iressa (an EGFR-specific inhibitor) and CI-1033 (an inhibitor that blocks all four ErbB family
members), inhibit proliferation and anchorage-independent growth, as well as radiosensitize
SUM149 cells in vitro (14,24). Basal-like breast cancers are found in approximately 40% of
patients with inflammatory breast cancer, representing one of the most aggressive forms of
breast cancer (26). In a recent Phase II clinical trial of patients with EGFR+ inflammatory
breast cancer, only 1 of 15 patients responded to lapatinib monotherapy (27). Consistent with
this finding, our analysis of the basal-like/EGFR+ SUM149 cells showed that lapatinib
monotherapy was ineffective at inhibiting tumor growth. In contrast, when lapatinib was
combined with RT, a synergistic interaction was seen, causing a significant reduction in tumor
growth, with an average enhancement ratio of 2.75 for the study duration.
In the SUM225 HER2+ xenografts, tumor growth was strongly inhibited by lapatinib alone,
with durable growth inhibition evident long after drug withdrawal. This result is consistent
with in vitro data showing that lapatinib greatly inhibits the growth of HER2+ breast cancer
cells (28) and with recent clinical trials in which HER2+ breast cancer patients responded to
lapatinib monotherapy (29,30). Although we did not observe radiosensitization with lapatinib
during early points in the SUM225 xenografts, statistically significant tumor growth inhibition
was observed starting at Day 97 in the lapatinib plus RT arm and persisted through study
termination (Day 138), producing an enhancement ratio of 1.43 from Days 97 to 138 and an
overall average enhancement ratio of 1.25 for the entire study duration (Days 0–138). The
degree of radiosensitization by lapatinib for both the EGFR+ SUM149 and HER2+ SUM225
xenographs was similar to what has been reported in preclinical radiosensitization studies of
head-and-neck cancer cell lines with cetuximab (31,32), an EGFR inhibitor clinically shown
to radiosensitize and improve survival (12).
Thus, our study results support the feasibility of combining RT with pharmacologic inhibitors
that target EGFR or HER2 in breast cancer patients. We recently reported the results from a
small Phase II study that evaluated trastuzumab (Herceptin), an anti-HER2 antibody, plus RT
followed by surgery in heavily pretreated, chemotherapy-refractory, HER2+ breast cancer
patients. Of the 7 patients who underwent combined trastuzumab plus RT followed by surgery,
3 (43%) showed a pathologic response (complete response or microscopic residual disease)
compared with a response of 5% in a comparison cohort (2 of 38 patients) (33). It remains
important to assess whether lapatinib can also radiosensitize breast cancer and whether
lapatinib can radiosensitize trastuzumab-resistant breast cancer.
As a drug class, EGFR inhibitors have shown clinical efficacy against various cancer types;
however, their use has been limited by a lack of biomarkers to predict and better select those
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patients most likely to respond to therapy (10,34,35). In the basal-like/EGFR+ SUM149
xenograft model, lapatinib-mediated radiosensitization correlated with inhibition of
downstream signaling to ERK1/2, which was not observed with either lapatinib or RT alone.
Recent studies from our laboratory (36) have demonstrated that radioresistance in basal-like/
EGFR+ breast cancer cells results from activation of the Raf>MEK>ERK pathway and that
both lapatinib and the MEK-inhibitor CI-1040 can radiosensitize these cell lines in vitro.
Consistent with our data, an analysis of 46 breast tumor cell lines by Mirzoeva et al. (37)
showed that cell lines of the basal-like subtype were more sensitive to inhibitors of MEK than
those of luminal origin.
Early studies in xenografts using HER2+ BT474 breast tumor cells showed lapatinib response
correlated with partial inhibition of ERK1/2 and complete inhibition of AKT (28,38). In our
HER2+ SUM225 xenografts, radiosensitization by lapatinib correlated with inhibition of
downstream signaling of AKT, but not ERK1/2, suggesting that AKT is a better marker of
lapatinib response in HER2+ breast cancers. In addition, the high degree of lapatinib sensitivity
in the SUM225 cells could be imparted through the combined inhibition of HER2 and EGFR,
because these cells are known to express extremely high levels of HER2 with some concurrent,
but much lower, levels of EGFR. Given that approximately 35% of HER2+ breast cancers are
also EGFR+ (39), profiling breast cancer patients to include EGFR status, along with estrogen
receptor, progesterone receptor, and HER2 status, would allow for better selection among the
various therapeutic agents that target the EGFR family of receptors.
Conclusion
Although EGFR and HER2 activate common downstream signaling pathways, our studies have
shown that fundamental differences exist between EGFR and HER2 response to RT, providing
insight into the divergent consequences of EGFR and HER2 signaling and inhibition. A model
based on the present study correlates lapatinib-mediated radiosensitization of EGFR+ cells
with ERK1/2 inhibition in basal-like/EGFR+ cells and with AKT inhibition in HER2+ cells.
Importantly, our results suggest that although EGFR+ breast cancers appear unresponsive to
lapatinib monotherapy, the combination of lapatinib plus RT might provide a therapeutic option
for patients with basal-like/EGFR+ breast cancers, who currently have few therapeutic options
(40). In addition, HER2+ breast cancer patients who are candidates for adjuvant RT could
experience better outcomes with longer response durations with combined RT and lapatinib.
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Lapatinib-mediated radiosensitization of SUM149 basal-like/epidermal growth factor
receptor-positive (EGFR+) breast cancer xenografts. (A) SUM149 tumors were grown to a
tumor diameter of 10 mm, treated with lapatinib (30 or 100 mg/kg twice daily at 6-h intervals)
or vehicle for total of five treatments within 2.5 days. EGFR was immunoprecipitated and
analyzed by Western blotting with anti-phosphotyrosine antiserum. (B) Tumors grown to 100
mm3 and treated with either lapatinib (100 mg/kg twice daily) or vehicle for 10 days starting
at Day –10 and radiotherapy at 2 Gy/fraction administered for 3 consecutive days starting at
Day –4. Tumor volume changes were normalized to baseline (Day –10) and plotted over time
for each treatment group. C = vehicle control; L = lapatinib; R = radiotherapy; L+R = lapatinib
plus radiotherapy. (C) Tumor growth rates = the slopes of growth curves during study duration
for each treatment group. (D) Synergy assessment = the ratio of expected/observed average
fractional tumor volumes (FTV) during study duration for lapatinib plus radiotherapy.
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Lapatinib-mediated radiosensitization of SUM225 HER2+ breast cancer xenografts. (A)
Tumors were treated as described in Fig. 1, and tumor volume changes normalized to baseline
(Day –10) and plotted over time for each treatment group. C = vehicle control; L = lapatinib;
R = radiotherapy; L+R = lapatinib plus radiotherapy. (B) Tumor growth rates = the slopes of
growth curves for study duration for each treatment group.
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Radiosensitization by lapatinib correlates with inhibition of ERK1/2 in EGFR+/basal-like cells
and with AKT in HER2+ breast cancer cells. (A) Tumors from basal-like/EGFR+ SUM149
xenografts were processed for immunohistochemistry with phosphorylated ERK1/2 antiserum
and quantified from mice treated with lapatinib, radiotherapy, lapatinib plus radiotherapy, or
vehicle control. (B) Sample immunohistochemistry staining of SUM149 tumors with
phosphorylated ERK1/2 serum at 400×. Similarly, tumors from HER2+ SUM225 xenografts
were processed for immunohistochemistry with phosphorylated AKT antiserum and (C)
quantified. (D) Sample immunohistochemistry of SUM225 tumors with phosphorylated AKT
serum at 400×. Open arrows indicate areas of increased staining; solid arrows, areas of reduced
staining.
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